EpilepsyGTx secures a $33 million Series A round to advance innovative gene therapies

Marco Zingaro Europe Legal Chronicle
Tagged:

A&O Shearman advised XGEN Venture, while Ashurst supported British Patient Capital. EpilepsyGTx, a UK‑based biotechnology company focused on the research and development of gene therapies for…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Marco Zingaro

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here